IQVIA Holdings Inc. (IQV) AI Stock Analysis

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and comprehensive clinical research services tailored for the life sciences industry globally. Operating across the Americas, Europe, Africa, and the Asia-Pacific, the company is organized into three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers cloud-based applications, real-world evidence capabilities, and strategic consulting. The Research & Development Solutions segment provides project management, clinical monitoring, virtual trials, and specialized central and genomic laboratory services. The Contract Sales & Medical Solutions segment focuses on healthcare provider and patient engagement, scientific strategy, and medical affairs support.

Between FY2021 and FY2025, IQVIA's revenue expanded from $13.87B to $16.31B, reflecting a 5-year revenue CAGR of 7.5% from FY2020 to FY2025. Annual net income increased from $966.0M in FY2021 to $1.36B in FY2025, while diluted EPS grew from $9.03 to $11.93. Gross margin was 33.5% in FY2021 and 33.3% in FY2025, while operating margin rose from 10.0% to 13.4%. Trailing twelve month revenue reached $16.98B with an 8.1% profit margin and EPS of $8.05. In the latest quarter ended June 30, 2026, revenue increased 8.7% year-over-year, while quarterly earnings declined 0.6%.

As of June 30, 2026, IQVIA held $2.08B in cash and short-term investments alongside $16.24B in total debt, resulting in net debt of $14.16B. The company recorded a current ratio of 0.71 and a debt-to-equity ratio of 2.63 on $6.17B of shareholders' equity. In FY2025, operating cash flow reached $2.65B and free cash flow totaled $2.05B. Capital expenditures were $603.0M, while share buybacks totaled $1.24B, contributing to a 5-year share count change of -13.4%.

At a last close of $266.90, IQVIA trades at a trailing P/E of 33.2x and a forward P/E of 18.4x, compared to the median of its S&P 500 Healthcare peers of 27.2x and 16.5x, respectively. The enterprise value is $58.25B, with an EV/EBITDA of 16.5x versus the peer median of 15.0x. Its price-to-sales ratio is 2.6x, below the peer group median of 3.4x. Over the past 12 months, the stock returned 29.7% against 16.8% for the S&P 500, though its 5-year return of 7.3% trails the index return of 83.0%.

Wall Street coverage includes 16 Strong Buy, 3 Buy, and 3 Hold ratings, with no Sell or Strong Sell recommendations. The mean price target of $299.11 sits 12.1% above the last close of $266.90. For the fiscal year ending December 31, 2026, consensus estimates project EPS of $12.96 on revenue of $17.42B. For the subsequent year, 22 analysts expect EPS of $14.42 on revenue of $18.47B. IQVIA beat EPS estimates in each of the past 4 quarters, and its next earnings date is October 27, 2026.

This page is an AI-written research summary of IQVIA Holdings Inc. (IQV). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: IQV income statement, IQV balance sheet, IQV key metrics, IQV analyst forecast, IQV chart. See the IQV stock overview for the latest quote and news.